Inotiv, Inc. (NASDAQ:NOTV) Shares Acquired by Thurston Springer Miller Herd & Titak Inc.

Thurston Springer Miller Herd & Titak Inc. increased its holdings in shares of Inotiv, Inc. (NASDAQ:NOTV) by 612.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 127,257 shares of the company’s stock after acquiring an additional 109,397 shares during the quarter. Thurston Springer Miller Herd & Titak Inc.’s holdings in Inotiv were worth $527,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of NOTV. American Century Companies Inc. grew its holdings in Inotiv by 109.6% in the 2nd quarter. American Century Companies Inc. now owns 295,589 shares of the company’s stock valued at $491,000 after buying an additional 154,541 shares in the last quarter. King Luther Capital Management Corp boosted its position in shares of Inotiv by 101.4% during the 2nd quarter. King Luther Capital Management Corp now owns 198,600 shares of the company’s stock valued at $330,000 after acquiring an additional 100,000 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Inotiv by 29.9% in the second quarter. Renaissance Technologies LLC now owns 164,164 shares of the company’s stock valued at $273,000 after purchasing an additional 37,800 shares during the period. Geode Capital Management LLC grew its stake in shares of Inotiv by 7.7% in the 3rd quarter. Geode Capital Management LLC now owns 250,895 shares of the company’s stock valued at $427,000 after buying an additional 18,039 shares during the period. Finally, KPP Advisory Services LLC grew its position in Inotiv by 4.5% in the second quarter. KPP Advisory Services LLC now owns 238,138 shares of the company’s stock worth $395,000 after acquiring an additional 10,347 shares during the period. Hedge funds and other institutional investors own 18.17% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Lake Street Capital raised Inotiv from a “hold” rating to a “buy” rating and raised their price objective for the stock from $2.00 to $4.00 in a research report on Monday, September 30th.

Inotiv Stock Up 0.9 %

Inotiv stock opened at $4.26 on Thursday. The company has a market capitalization of $110.82 million, a PE ratio of -1.02 and a beta of 3.59. The company has a debt-to-equity ratio of 2.29, a quick ratio of 1.22 and a current ratio of 1.37. Inotiv, Inc. has a fifty-two week low of $1.23 and a fifty-two week high of $11.42. The firm has a 50 day moving average price of $4.00 and a 200 day moving average price of $2.52.

Insider Transactions at Inotiv

In other Inotiv news, Director Michael J. Harrington acquired 10,000 shares of the stock in a transaction dated Friday, December 6th. The stock was acquired at an average price of $3.98 per share, with a total value of $39,800.00. Following the completion of the purchase, the director now owns 37,500 shares in the company, valued at $149,250. This trade represents a 36.36 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David Landman bought 23,529 shares of the business’s stock in a transaction that occurred on Thursday, December 19th. The shares were acquired at an average cost of $4.25 per share, for a total transaction of $99,998.25. Following the completion of the purchase, the director now owns 176,851 shares in the company, valued at $751,616.75. This trade represents a 15.35 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 71,029 shares of company stock worth $314,248 over the last ninety days. Company insiders own 5.80% of the company’s stock.

About Inotiv

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.